This site is intended for health professionals only

Lundbeck initiates new trial


Lundbeck has strengthened its pipeline of pharmaceuticals in clinical development by initiating phase I clinical studies with Lu AA38466 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans.

Lu AA38466 is an ion channel modulator and has demonstrated convincing effects in a number of animal models of neurological disorders.

“Focus at Lundbeck Research is to discover innovative compounds that address unmet needs for patients. Lu AA38466 is an example of a new generation of compounds with a great potential for treatment of certain neurological conditions,” says Executive Vice President Peter Høngaard Andersen, Head of Research at Lundbeck.


Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine